Next Phase Newsletter

A private equity investment firm seeks early stage companies to form and establish, as well as investing to bridge the gap between late stage companies in Israel and companies with sales activity in the U.S. and Europe (“platforms”). For early-stage companies, the firm typically invests from a few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. The firm may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in diabetes, obesity, heart failure, structural heart, pulmonary hypertension, currently looking at neurology and urology, and is open to new areas of focus. For late-stage/platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm was founded in 2017 and has multiple offices in Europe. The firm makes venture investments across the life science sector from a €100 million fund.  The firm invests throughout Europe, with a focus on the Nordic region and Western Europe; initial investments are typically €4-6 million. The firm prefers to act as a lead investor, but may consider following on as part of a strong syndicate.

The firm invests across the life science sector, including therapeutics, devices and diagnostics.  The firm only invests in products that are subject to regulation.  The firm will consider any indication or modality. The firm prefers to invest in assets that are at least ready to go into clinical trials.

The firm focuses on assets that they consider to have below the average risk level of their peer group.  The firm prefers to lead investments, particularly in its home region, and performs their own due diligence even in cases in which they act as a co-investor.  While the firm does not exclude any areas of opportunity, there is a focus on de-risked assets and areas in which the execution and regulatory risk for the asset is reduced.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment firm based in Europe focuses on investing in digital health, devices and diagnostics technologies. Though an early investor, the firm looks for companies that have some proof of concept data. The firm primarily invests in companies within the country where the firm is based, but will consider investments in North America, all of Europe and Israel. The firm generally looks to invest between 100K-2M EUR in their portfolio companies.

The firm will invest in digital health as well as diagnostics and devices as well as regenerative medicine technologies. For diagnostics and devices, the firm prefers companies with a digital component. In addition, the firm prefers devices without complex regulatory requirements. The firm is agnostic with regards to indication.

The firm is willing to lead or co-invest, although they are most likely to lead if investing in Hungary. Generally, the firm prefers to have a board or an observer seat after investing. Within the life sciences, the firm prefers to invest in teams with industry experience, especially for companies located outside of the country where the firm is based.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large biotech company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics globally for patients suffering from inflammatory and auto-immune diseases, has built a clinical late stage therapeutics pipeline and is seeking collaborations with companies with compelling early-stage programs and technologies within its core therapeutic areas of interest, and is willing to consider multiple partnering structures ranging from investments (active or passive) to in-licensing. While primarily interested in therapeutics, assuming a fit with the firm’s areas of interest, the firm is willing to consider partnerships and investments around other technologies. Furthermore, the firm is willing to partner with companies across the globe.

The firm’s areas of interest are in inflammation and auto-immune conditions, with a focus on GI and dermatologic disease. Also of interest are any technologies relating to the microbiome. As a secondary interest, the firm will also consider therapeutics in the cardiovascular space.

Due to their flexibility as investors, the firm can assume varying roles in a partnership depending on the level of investment. When investing alongside other firms, the firm will not necessarily require exclusive rights to the assets. For larger investments, where the firm is supporting the majority of development activities, they generally will assume an involved role as a more pro-active partner with the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences investment fund dedicated to accelerating the growth of seed-stage therapeutics companies with a partnership with a USA-based family investment office, seeks to make 3-5 new investments per year allocating up to $250,000 per company. The firm invests in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe with multiple funds raised to date, generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 2 million. The firm plans to make 15-20 investments in the next 3 years and the firm will invest in companies based in Europe with a focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, etc. The firm focuses on companies developing biotech platforms, research tools and nutrition in preclinical and clinical stages. The firm will not invest in drug development companies or medical device companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, and technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm founded in 2018 and based in China is focused on big data and IOT-related healthcare investment opportunities. The firm is currently managing a 500 million RMB fund and is actively looking to invest 10-20 new deals in the following 12 months. The firm invests mostly in Medical Devices, Diagnostics, and Digital Health companies but will also consider drugs in applicable cases. The firm is currently looking for new opportunities globally, however, following China’s latest healthcare development strategy would be an important consideration although not required for their investment opportunities. The size of investment can vary from 10 – 30 million RMB depending on the deal.

The firm is interested in medtech, diagnostics, and digital health companies that are seeking for early financing round. The firm’s sweet spot is to invest in angel to pre-A round. The firm will not invest in B round or later rounds. The firm is especially interested in technology with a big-data component. The firm has invested in molecular diagnostics and digital health companies. The firm is opportunistic in terms of subsectors and indications.

The firm is seeking to invest in management teams with strong research or industry background. Management teams that graduated from the world’s top universities or has worked for big pharma is a plus. The firm also prefers serial entrepreneurs with successful track records.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.